Intraperitoneal Atomization of Levobupivacaine During Gynaecological Laparoscopic Procedures ; Impact on Pain, Opioid Use and Length of Recovery Room Stay (IPLA).

Overview

In this study, we will compare 3 treatments. The first group of patients will receive the standard treatment (paracetamol, diclofenac and an opioid if necessary) with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) . The second group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional injection of the local anesthetic ( 0.5% levobupivacaine, non -diluted) in the peritoneal cavity via a trocar both at the beginning and the end of the surgery . The third group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional intraperitoneal atomization of the local anesthetic. We will use non-diluted 0.5% levobupivacaine delivered directly onto the target sites both at the beginning and the end of surgery. The drug will be delivered using OptiSpray® surgical spray device, an inexpensive delivery system that will direct a fine mist of drug directly to the areas of the peritoneal cavity that are theoretically the cause of post-op pain (diaphragms, peritoneal abdominal surface, surgical dissection site). Our primary goal is to assess the efficacy of intraperitoneal atomization of levobupivacaine in reducing postoperative pain and of opioid requirements in patients undergoing gynecological laparoscopic procedures in one-day surgery.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 13, 2014

Interventions

  • Drug: Standard Injection of Levobupivacaine in portal sites.
    • All port sites will be injected with 0.1ml/kg levobupivacaine at the end of surgery, after trocar removal.
  • Drug: Additional injection of 0,5% levobupivacaine.
    • Immediately following insufflation 0.15ml/kg levobupivacaine will be injected in the peritoneal cavity via a trocar. At the end of the surgery, this process will be repeated with the same dose at 0.15ml/kg.
  • Drug: Intraperitoneal atomization of levobupivacaine.
    • Immediately following insufflation the Optispray® surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the study drug will be delivered as an atomized spray in the following volumes: Each subdiaphragmatic area 0.05 ml/kg Dome of abdomen then settling onto bowel 0.05 ml/kg Surgical dissection site 0.05 ml/kg At the end of the surgery – this process will be repeated with the same doses at 0.15 ml/kg.

Arms, Groups and Cohorts

  • Active Comparator: Infiltration of portal sites with 0,5% levobupivacaine.
    • The first group of patients will receive the standard treatment (paracetamol, diclofenac and an opioid if necessary) with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine).
  • Experimental: Additional injection of 0.5% levobupivacaine via a trocar
    • The second group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional injection of the local anesthetic ( 0.5% levobupivacaine, non -diluted) in the peritoneal cavity via a trocar both at the beginning and the end of the surgery.
  • Experimental: Additional intraperitoneal atomization of levobupivacaine.
    • The third group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional intraperitoneal atomization of the local anesthetic.

Clinical Trial Outcome Measures

Primary Measures

  • Post-operative pain intensity after laparoscopic gynaecological surgery in 1-day hospital setting.
    • Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day.
    • Pain evaluation will be done using an 11-point numeric rating scale (0 = no pain, 10 = worst pain possible).
  • Post-operative shoulder pain after laparoscopic gynecological procedure in 1-day hospital setting.
    • Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day.
    • Pain evaluation will be done using an 11-point numeric rating scale (0 = no pain, 10 = worst pain possible).

Secondary Measures

  • Post-operative opioid analgesic requirements after laparoscopic gynaecological surgery.
    • Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day.
    • Piritramide 0,05 mg/kg
  • Post-operative pain intensity after laparoscopic gynaecological surgery from hospital discharge until 24 hrs post-operatively.
    • Time Frame: Patients will be followed until 24 hours post-operatively.
    • Patients will be asked to evaluate their pain at 6 hrs, 12 hrs, 18 hrs and 24 hrs post-operatively using an 11-point numeric rating scale (0=no pain and 10= worse pain possible) and report it by telephone.
  • Post-operative shoulder pain after laparoscopic gynecological surgery from hospital discharge until 24 hrs post-operatively.
    • Time Frame: Patients will be followed until 24 hours post-operatively.
    • Patients will be asked to evaluate their pain at 6 hrs, 12 hrs, 18 hrs and 24 hrs post-operatively using an 11-point numeric rating scale (0=no pain and 10= worse pain possible) and report it by telephone.
  • Post-operative nausea and vomiting (PONV) in the first 24 hrs post-operatively, after laparoscopic gynecological surgery.
    • Time Frame: Patients will be followed until 24 hours post-operatively.
    • Nausea and vomiting will be evaluated every 15′ during the first 2 hrs, every 30′ until hospital discharge, using a PONV verbal descriptor scale 0 to 2 points : 0=no nausea, 1=any nausea, 2 =vomiting. After discharge, patients wil be asked to evaluate PONV at 6 hrs, 12 hrs, 18 hrs and 24 hrs post-operatively and report it by telephone.
  • Post-operative sedation until hospital discharge, after laparoscopic gynecological surgery.
    • Time Frame: Patients will be followed up to 6 hrs post-operatively.
    • Sedation will be evaluated at 0, 1, 2, 4, 6 hrs post-operatively, using the Ramsay sedation score (1= anxious and agitated, 2= cooperative, tranquil, oriented, 3=responds only to verbal commands, 4= asleep with brisk response to light stimulation, 5=asleep without response to light stimulation, 6=non-responsive).
  • Time until discharge from recovery room.
    • Time Frame: Up until discharge from recovery room post-operatively, probably a few hours.
    • Discharge criterion: aldrete ≥ 9/10.
  • Time until discharge from hospital.
    • Time Frame: Patients will be followed until an estimated 24 hours post-operatively.
    • Discharge criterion : modified aldrete ≥ 12/14.

Participating in This Clinical Trial

Inclusion Criteria

  • Patients who are planned for gynaecological laparoscopic interventions on an ambulatory basis. Exclusion Criteria:

  • Less than 18 year old. – Weight less than 50 kg and more than 80 kg. – Pregnant. – Prisoners; – Allergic to topical anesthetics (Amides specifically). – Allergic to Opioids as a class. – Currently or within the last 30 days been prescribed an opiate medication. – Chronic pain syndrome.

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Ghent
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Marc Coppens, mD, Principal Investigator, University Hospital, Ghent

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.